Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial

Video

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Following results that were reported at the 2020 San Antonio Breast Cancer Symposium, investigators of the phase 3 RxPONDER trial (NCT01272037) hope to further evaluate the clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and an Oncotype DX Recurrence Score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of both the Glenn Family Breast Center and of breast medical oncology at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about next steps following the phase 3 RxPONDER trial.

Transcription:

I have a lot of work to do. We were only reporting at about 50% of the events, so we’re still awaiting additional events. And we’ll put this out as data come. We’ll also be reporting things like quality-of-life outcomes and other end points. And then there’s also a translational medicine component to this where we’ve collected primary tissue and lymph nodes involved that weren’t involved, in the hopes that we could also look at additional predictors or prognostic signatures that can help inform this patient population and potentially future studies as well.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content